TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Clinical trial NCT07190300 · RECRUITING
Trial details
- NCT number
- NCT07190300
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-13
- Primary completion
- 2032-08-02
- Enrollment
- 181
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.